Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melaleuca alternifolia essential oil, widely known as tea tree oil (TTO), is a botanical extract obtained via steam distillation from the leaves of the Australian native plant *Melaleuca alternifolia*. The oil is characterized by its high content of terpinen-4-ol, which provides documented antibacterial, antifungal, and antiviral properties. In clinical research conducted by Briant Burke, MD, MS, TTO was evaluated as a topical treatment for molluscum contagiosum in children, often in combination with iodine. Its mechanism of action involves the physical disruption of viral lipid envelopes and the loss of cellular integrity. Clinical data from Australian trials (e.g., ACTRN12610000984099) indicated that topical application significantly reduces the number of visible lesions with a favorable safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melaleuca alternifolia essential oil.